Stock market today: S&P 500 rides Apple-led tech rally to close higher
Investing.com -- A federal judge has denied Novartis (SIX:NOVN)’ request for a preliminary injunction that would have prevented MSN Pharmaceuticals from selling a generic version of heart medication Entresto.
U.S. District Judge Evelyn Padin in Newark, New Jersey reversed her previous ruling that had favored Novartis in its trade dress infringement claim against MSN.
MSN plans to market its generic version under the name Novadoz, which combines elements of Novartis and its Sandoz (SIX:SDZ) generics division names.
In her Tuesday decision, Judge Padin stated that Novartis’ exclusivity over Entresto should not continue indefinitely, adding that "denial of injunctive relief and the availability of a generic alternative to a life-savings medication is in the public interest."
The judge noted that Novartis’ patent-related exclusivity for Entresto expires today, July 16.